"In 1962, the anti-addictive property of ibogaine was inadvertently discovered by 19-year-old heroin addict Howard Lotsof.58 Lotsof was part of an experimental group of mostly 20-something Caucasians attending college.59 The group, which included seven heroin addicts, shared a common interest in experimenting and subjectively evaluating their experiences with various psychoactive drugs, including Mescaline, LSD, DMT, and psilocybin,60 in an effort to determine the psychotherapeutic value of hallucinogenic drugs.61 As psychedelic drugs were not illegal at the time, Lotsof had access to many of these drugs through his company, S & L Laboratories.62 Rather than simply providing the hallucinogenic, euphoriant high the group anticipated, the heroin addicts noticed that ibogaine actually alleviated their craving for heroin.63 Lotsof ceased using heroin, cocaine, and all other drugs during the six months following his initial dose of ibogaine, an effect most members of the group shared.64

"In 1986, more than two decades after his initial discovery, Lotsof: [sic] founded NDA International (NDA); obtained patents for the use of ibogaine in treating opiate, cocaine, amphetamines, and alcohol addictions under the name Endabuse; and started unofficially distributing ibogaine to addicts in Holland.75"


Donnelly, Jennifer R, "The Need for Ibogaine in Drug and Alcohol Addiction Treatment," The Journal of Legal Medicine (Schaumburg, IL: American College for Legal Medicine, March 2011), Vol. 32, Issue 1, pp. 100 and 101.